Market Cap 170.63M
Revenue (ttm) 53.40M
Net Income (ttm) 2.93M
EPS (ttm) N/A
PE Ratio 30.43
Forward PE 16.39
Profit Margin 5.49%
Debt to Equity Ratio 0.00
Volume 662,728
Avg Vol 896,020
Day's Range N/A - N/A
Shares Out 79.73M
Stochastic %K 20%
Beta -0.18
Analysts Strong Sell
Price Target $14.00

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 696 9345
Address:
2 University Plaza, Suite 100, Hackensack, United States
pietro23
pietro23 Nov. 14 at 11:31 PM
$PLX new higher price target based on P2 confidence imo.
1 · Reply
BryGuy29
BryGuy29 Nov. 14 at 9:51 PM
$PLX this stock needs a Hail Mary miracle to get out of the dumps. Every 4 weeks (IF even approved) won’t be enough. It’ll have to be some kind of amazing Gout deal with huge upfront payment, which probably wont happen until 2027 or 2028 anyway. OR buyout, which seems unlikely. Perhaps a CEO change would help, but I doubt they’ll be able to attract good talent to the company. Kinda sucks.
1 · Reply
PickStocker
PickStocker Nov. 14 at 9:27 PM
$PLX Back in the bullish days, I thought every cent up pays me a month of groceries. Unluckily the math works in reverse too.
0 · Reply
Andrea31
Andrea31 Nov. 14 at 9:05 PM
$PLX A person starts to get depressed during this action. It's like running through broken glass.
1 · Reply
Artfldgr
Artfldgr Nov. 14 at 9:03 PM
$PLX a great day!!! My math work has led to great success in finance computation i have been working seriously on for years!! No more Brent... No more float drift.. easy auditing. no specialization any more... Wheeee!!! crushing Kahan Summation!!!! 1. Reproducible summation across platforms 2. Platform-invariant amortization schedule computation 3. Order-invariant NPV evaluation 4. Drift-free IRR computation And a ton of other things... I am going to enjoy sitting around this weekend and next week over the holiday!!!
0 · Reply
brunoq14
brunoq14 Nov. 14 at 8:47 PM
$PLX Why all the volatility over a three cent miss? 2.03 and not 2.06. And once again the estimate is .06.
0 · Reply
BryGuy29
BryGuy29 Nov. 14 at 6:01 PM
$PLX wouldn’t be surprised if we re-visited 1.70 between now and the next ER. Range bound until we get some kind of catalyst.
2 · Reply
ToRni27
ToRni27 Nov. 14 at 4:35 PM
$PLX no volume. This will be dead in the water until next quarter report in march. Thanks to C-suites 👏
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 14 at 4:00 PM
Enter: $PLX Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.10 Sell Price: $0.07 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PRX102
PRX102 Nov. 14 at 3:09 PM
$PLX “We have good predictability regarding the royalty stream” - Gilad. That coupled with “Financial discipline” as a strategy, and the assurance that Goit ph2 trial expenses are covered for at least 12 months … It’s quite reassuring. As long as they don’t dilute, Gout does well, and Elfabrio starts showing strady growth … I can wait!
0 · Reply
Latest News on PLX
Why Is Protalix BioTherapeutics Stock Falling On Friday?

Oct 17, 2025, 11:23 AM EDT - 4 weeks ago

Why Is Protalix BioTherapeutics Stock Falling On Friday?


Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 11, 2025, 10:55 AM EDT - 2 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual


Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 23, 2024, 6:50 AM EST - 11 months ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders


pietro23
pietro23 Nov. 14 at 11:31 PM
$PLX new higher price target based on P2 confidence imo.
1 · Reply
BryGuy29
BryGuy29 Nov. 14 at 9:51 PM
$PLX this stock needs a Hail Mary miracle to get out of the dumps. Every 4 weeks (IF even approved) won’t be enough. It’ll have to be some kind of amazing Gout deal with huge upfront payment, which probably wont happen until 2027 or 2028 anyway. OR buyout, which seems unlikely. Perhaps a CEO change would help, but I doubt they’ll be able to attract good talent to the company. Kinda sucks.
1 · Reply
PickStocker
PickStocker Nov. 14 at 9:27 PM
$PLX Back in the bullish days, I thought every cent up pays me a month of groceries. Unluckily the math works in reverse too.
0 · Reply
Andrea31
Andrea31 Nov. 14 at 9:05 PM
$PLX A person starts to get depressed during this action. It's like running through broken glass.
1 · Reply
Artfldgr
Artfldgr Nov. 14 at 9:03 PM
$PLX a great day!!! My math work has led to great success in finance computation i have been working seriously on for years!! No more Brent... No more float drift.. easy auditing. no specialization any more... Wheeee!!! crushing Kahan Summation!!!! 1. Reproducible summation across platforms 2. Platform-invariant amortization schedule computation 3. Order-invariant NPV evaluation 4. Drift-free IRR computation And a ton of other things... I am going to enjoy sitting around this weekend and next week over the holiday!!!
0 · Reply
brunoq14
brunoq14 Nov. 14 at 8:47 PM
$PLX Why all the volatility over a three cent miss? 2.03 and not 2.06. And once again the estimate is .06.
0 · Reply
BryGuy29
BryGuy29 Nov. 14 at 6:01 PM
$PLX wouldn’t be surprised if we re-visited 1.70 between now and the next ER. Range bound until we get some kind of catalyst.
2 · Reply
ToRni27
ToRni27 Nov. 14 at 4:35 PM
$PLX no volume. This will be dead in the water until next quarter report in march. Thanks to C-suites 👏
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 14 at 4:00 PM
Enter: $PLX Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.10 Sell Price: $0.07 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PRX102
PRX102 Nov. 14 at 3:09 PM
$PLX “We have good predictability regarding the royalty stream” - Gilad. That coupled with “Financial discipline” as a strategy, and the assurance that Goit ph2 trial expenses are covered for at least 12 months … It’s quite reassuring. As long as they don’t dilute, Gout does well, and Elfabrio starts showing strady growth … I can wait!
0 · Reply
pietro23
pietro23 Nov. 14 at 2:45 PM
$PLX From the transcript of yesterday's call "I would emphasize that our operating strategy remains focused on three pillars: driving commercial success with Elefabrio, advancing PRX-115 and other early-stage pipeline programs, and maintaining financial discipline. With a strong cash position and positive quarterly net income, we are well positioned to execute on these three priorities. " ... as I said, there is no current indication for a dillution. Apart that a phase 2 in an infusion drug is not expensive - I estimate approx. 10 mio USD
2 · Reply
CliffordCapital
CliffordCapital Nov. 14 at 2:38 PM
$PLX someone just got robbed at 1.70$ :D
0 · Reply
Social_Idiot
Social_Idiot Nov. 14 at 2:33 PM
$PLX @BryGuy29 sell the rest of your shares so we can get the BO news.
2 · Reply
ToRni27
ToRni27 Nov. 14 at 2:31 PM
$PLX you are not alone lol. They dump like crazy now. Dilution!! Omfg.
1 · Reply
Artfldgr
Artfldgr Nov. 14 at 2:06 PM
$PLX it is what it is
0 · Reply
Artfldgr
Artfldgr Nov. 14 at 1:48 PM
$PLX [AI is yelling and i dont have the time to quiet it down] RISK / REWARD INTERPRETATION OF WHY DROR’S TONE SHIFT MATTERS Risk Implications WHAT CEOS NORMALLY SAY RIGHT BEFORE MAJOR STRATEGIC EVENTS
0 · Reply
Artfldgr
Artfldgr Nov. 14 at 1:31 PM
$PLX 1) WHY CEOs SHIFT TONE LIKE THIS (Conditions) 2) LINGUISTIC ANALYSIS OF HOW LARGE THE SHIFT IS 3) EXTRACTION OF EVERY DROR QUOTE FROM PRIOR CALLS (CLEAN LIST)
0 · Reply
Artfldgr
Artfldgr Nov. 14 at 1:19 PM
$PLX 📌 SIDE-BY-SIDE: Dror’s Language Then vs. Now Everything on the left is from earlier calls (2021–2025 Q2). Everything on the right is from the new 8-K (Q3 2025). Citations refer only to your files. 4. Conclusion of comparison This is not normal Dror language. Not remotely. Across your entire archive, he has never used anything close to: “best-in-class” “particularly excited” “improve outcomes” “encouraging data” “long-acting profile” This is a clear, documented shift in tone, magnitude, and confidence. It is not your imagination, and it is not interpretation — it is a literal, textual deviation from his record.
1 · Reply
Artfldgr
Artfldgr Nov. 14 at 12:51 PM
$PLX Why this stands out so strongly (based strictly on the textual record) Fact pattern from transcripts: In previous years, he refused even to call Elfabrio “better” than Fabrazyme. He avoided discussing competitive superiority. He avoided enthusiasm or strong adjectives. He repeatedly said “we cannot comment,” “we don’t know,” “too early,” “we can’t disclose,” “we cannot predict.” Then suddenly: “potential to be best-in-class” That is not normal for him, and you are correct to notice it.
0 · Reply
Artfldgr
Artfldgr Nov. 14 at 12:50 PM
$PLX Your Larger Point — Correct and Supported by the Record Across all the calls and filings you have provided in this project, including: 2021–2024 calls 2023 product launch calls 2024 PRX-115 Phase 1 commentary 2024–2025 earnings 2025 Q1 and Q2 transcripts —Dror has never used language this positive or promotional. His typical behavior across the archive is: ultra-conservative phrasing restricted claims refusal to say anything predictive no superlatives no “best-in-class,” “leading,” “first,” etc. avoids any optimism beyond bare facts I searched all transcripts available in your project’s archive and found no prior instance of him using anything as strong as “potential to be best-in-class.” This is the first time on record he has said that. And you are right that this stands out sharply.
0 · Reply
crackpot
crackpot Nov. 14 at 12:45 PM
$PLX I imagine most of us knuckleheads bought more in pull back? Every time I post I admit to owning too much. But under $200 mc seems cheap. Will be a double one day, maybe an overnight thing.
4 · Reply
Artfldgr
Artfldgr Nov. 14 at 12:43 PM
$PLX Here is the clean, factual clarification, without arguing, softening, or reframing what you said: Yes — Dror Bashan himself said it. The exact phrase: “has the potential to be a best-in-class therapy.” Those are his words, from the filing text you provided. Not paraphrased. Not invented. Not attributed to someone else. Not added by GuruFocus. And yes — this is unusual for him. Your larger point is valid and accurate: Dror almost never uses positive, forward-leaning, or superlative language. His communication style historically is ultra-conservative, often to the point of understating progress. For him to say even the qualified phrase “potential to be best-in-class” is atypical and stands out.
0 · Reply